-
GSK2838232
- names:
GSK2838232
- CAS號:
1443460-91-0
MDL Number: No data available - MF(分子式): C48H73ClN2O6 MW(分子量): 809.56
- EINECS:No data available Reaxys Number:No data available
- Pubchem ID:71580991 Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價格 (¥) | 現(xiàn)價(¥) | 特價(¥) | 庫存描述 | 數(shù)量 | 總計 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000654-10mg | 10mg | 99.26% | ¥ 5062.00 | ¥ 5062.00 | 2-3天 | ¥ 0.00 | ||
| YZM000654-5mg | 5mg | 99.26% | ¥ 3412.50 | ¥ 3412.50 | 2-3天 | ¥ 0.00 |
| 中文別名 | GSK2838232(1443460-91-0),GSK-2838232;GSK2838232;GSK 2838232;4-[[((3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-[(1R)-2-[(4-氯苯基)甲基-[2-(二甲基氨基)乙基]氨基]- 1-羥乙基] -5a,5b,8,8,11a-五甲基-2-氧代-1-丙-2-基-4,5,6,7,7a,9,10,11,11b,12,13 ,13a-十二烷基-3H-環(huán)戊[a] chrysen-9-基]氧基] -2,2-dime; |
| 英文別名 | GSK2838232(1443460-91-0),4-[[(3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-[(1R)-2-[(4-chlorophenyl)methyl-[2-(dimethylamino)ethyl]amino]-1-hydroxyethyl]-5a,5b,8,8,11a-pentamethyl-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3H-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dime; |
| CAS號 | 1443460-91-0 |
| Inchi | InChI = 1S / C48H73ClN2O6 / c1-30(2)40-34(52)26-48(37(53)29-51(25-24-50(10)11)28-31-12-14-32( 49)15-13-31)23-22-46(8)33(41(40)48)16-17-36-45(7)20-19-38(57-39(54)27-43( 3,4)42(55)56)44(5,6)35(45)18-21-47(36,46)9 / h12-15,30,33,35-38,53H,16-29H2, 1-11H3,(H,55,56)/ t33-,35 +,36-,37 +,38 +,45 +,46-,47-,48 + / m1 / s1 |
| InchiKey | MEOWKUXNVNJAMY-PZFKGGKESA-N |
| 分子式 Formula | C48H73ClN2O6 |
| 分子量 Molecular Weight | 809.56 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度≥ 50 mg/mL(61.76 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性狀 | 白色至灰白色固體粉末,Power |
| 儲藏條件 Storage conditions | 存放在陰涼干燥處,短期(數(shù)天至數(shù)周)在0-4℃,長期(數(shù)月至數(shù)年)在-56℃。保質(zhì)期2年。 |
GSK2838232(1443460-91-0)實驗注意事項:
1.實驗前需戴好防護眼鏡,穿戴防護服和口罩,佩戴手套,避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生,必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲,并交于專業(yè)生物廢氣物處理公司處理,以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:GSK2838232試劑,GSK2838232雜質(zhì),GSK2838232中間體,GSK2838232密度,GSK2838232合成,GSK2838232密度,GSK2838232溶解度,GSK2838232旋光度,GSK2838232閃點,GSK2838232購買,
| 產(chǎn)品說明 | (1443460-91-0)GSK2838232 GSK2838232是Betulin的衍生物,是一種新型的人類免疫病毒(HIV)成熟抑制劑,正在開發(fā)用于治療慢性HIV感染. |
| Introduction | GSK2838232(1443460-91-0)inhibit HIV reverse transcriptase activity across a broad panel of HIV isolates, extracted from patent WO/2013090664A1, compound51. |
| Application1 | |
| Application2 | |
| Application3 |
GSK2838232(1443460-91-0)是Betulin的衍生物,GSK2838232是一種新型的人類免疫病毒(HIV)成熟抑制劑,正在開發(fā)用于治療慢性HIV感染。GSK2838232是抗艾滋病毒劑,用于治療艾滋病和/或制止艾滋病毒感染傳播的藥物。這些不包括用于治療與艾滋病相關(guān)的癥狀或機會性感染的藥物.通過高含量成像確定抗病毒活性是在10 uM時抑制SARS-CoV-2誘導(dǎo)的Caco-2細胞的細胞毒性,作用時間為10 uM。
| 警示圖 | |
| 危險性 | warning |
| 危險性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害 |
| 安全防護 | P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡(如果有)并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理 |
| 備注 | 實驗過程中防止吸入、食入,做好安全防護 |
| Hatcher Mark Andrew, et al. Preparation of betulin derivatives for the treatment of HIV. From PCT Int. Appl. (2013), WO 2013090664 A1 20130620. |
GSK2838232(1443460-91-0)參考文獻:
1、US2018042944 藥物成分 2017-10-19
This web page summarizes information in PubChem about patent US-2018042944-A1. This includes chemicals mentioned, as reported , as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed, please visit the PubChem patents help page. The present Invention relates to long acting pharmaceutical compositions of betulin derivatives or pharmaceutically acceptable salts thereof, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
2、US2017348324 樺木的衍生物 2017-08-24
This web page summarizes information in PubChem about patent US-2017348324-A1. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed,
The present invention relates to compounds characterized by having a structure according to the following Formula I: n n n n n n n n n n , or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.
3、US2017252356 用木犀草素衍生物治療HIV的化合物和組合物 2017-03-21
This web page summarizes information in PubChem about patent US-2017252356-A1. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed。
The present invention relates to compounds characterized by having a structure according to the following Formula I: n n n n n n n n n n or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.
4、US2016120878 樺木的衍生物 2015-12-23 2016-05-05
This web page summarizes information in PubChem about patent US-2016120878-A1. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed,
The present invention relates to compounds characterized by having a structure according to the following formula I: n n n n n n n n n n n n or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.
5、US2014357643 樺木素衍生物 2014-08-18 2014-12-04
This web page summarizes information in PubChem about patent US-2014357643-A1. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed,
The present invention relates to compounds characterized by having a structure according to the following Formula I: n n n n n n n n n n , or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞

怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色,是通過細胞爬片是讓玻片浸在細胞培養(yǎng)基內(nèi),細胞在玻片上生長,主要用于組織學(xué),免疫組織化學(xué)...
2020/7/20 22:04:33

提取病毒RNA的實驗方法
提取病毒RNA方法分別有:異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26

9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55

Waxfilm 實驗室封口膜:技術(shù)與國際市場的雙重突破
在實驗室耗材領(lǐng)域,封口膜是保障實驗準確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來,Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40

Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破,是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07

各種微流控芯片鍵合方法的優(yōu)缺點
微流控芯片鍵合:目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接,每種方法都有各自的優(yōu)缺點。本文主要介紹聚酯...
2023/7/28 10:43:09

新一代微流控鍵合解決方案
微流控鍵合解決方案:微流控芯片制造的一個重要環(huán)節(jié),也是最容易被忽視的--芯片鍵合。其中一個重要因素是:微流控...
2023/7/27 12:44:28

熒光素鉀鹽使用說明
D-熒光素鉀鹽(K+)設(shè)計用于體外和體內(nèi)生物發(fā)光測定。D-熒光素的質(zhì)量和純度對于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11

如何選BSA(牛血清白蛋白)
如何選BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多種形式,如何選擇適合自己的牛血清白蛋白(BSA)是一...
2023/2/14 13:09:18

牛血清白蛋白(BSA)常見問題
牛血清白蛋白(BSA)常見問題:牛血清白蛋白(BSA)在實驗室中是通用的,可用于蛋白質(zhì)印跡、細胞組織培養(yǎng)、P...
2022/10/19 9:39:51



購物車 


